Stockscreener 앱 받기
12.31
6.88%
-0.91
시간 외 거래:
12.45
0.14
+1.14%
전일 마감가:
$13.22
열려 있는:
$13.25
하루 거래량:
617.04K
Relative Volume:
0.95
시가총액:
$672.09M
수익:
$8.78M
순이익/손실:
$-104.70M
주가수익비율:
-5.1941
EPS:
-2.37
순현금흐름:
$-82.68M
1주 성능:
+2.07%
1개월 성능:
+6.30%
6개월 성능:
+25.61%
1년 성능:
-9.35%
1일 변동 폭
$12.26
$13.31
1주일 범위
$11.66
$14.50
52주 변동 폭
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
12.31 | 658.44M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
What drives Stoke Therapeutics Inc. stock priceRecord-setting profit potential - Autocar Professional
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - Insider Monkey
What analysts say about Stoke Therapeutics Inc. stockBreakthrough investment results - Autocar Professional
Is Stoke Therapeutics Inc. a good long term investmentExceptional profit velocity - PrintWeekIndia
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
Stoke Therapeutics Inc. Stock Analysis and ForecastAccelerated profit realization - Autocar Professional
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st
Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus
Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada
Published on: 2025-07-18 11:35:29 - jammulinksnews.com
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 16, 2025 - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
How Stoke Therapeutics Inc. stock performs during market volatilityProven Trading Plan - Newser
What makes Stoke Therapeutics Inc. stock price move sharplyDaily Price Surge List - Newser
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago - Yahoo Finance
Canaccord Genuity Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail
Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Ariva
Biogen (BIIB) Presents Promising Data from Zorevunersen Studies - GuruFocus
Revolutionary Dravet Syndrome Treatment: Biogen's Zorevunersen Delivers Cognitive Gains in Phase 3 Trial - Stock Titan
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Business Wire
STOK files 8-K; releases data guiding Phase 3 EMPEROR dosing | IDXX SEC FilingForm 8-K - Stock Titan
Stoke Therapeutics Files $400 Million Mixed Shelf Offering - AInvest
Stoke Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Stoke Therapeutics (STOK) Announces $400M Mixed Securities Shelf Registration | STOK Stock News - GuruFocus
Unlocking Value in Stoke Therapeutics: The Strategic Power of a $400M Mixed Shelf Offering - AInvest
Stoke Therapeutics (STOK) Receives Continued 'Buy' Rating from N - GuruFocus
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Buy” from Analysts - Defense World
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):